MA51587B1 - Exon skipping oligomer conjugates for muscular dystrophy - Google Patents

Exon skipping oligomer conjugates for muscular dystrophy

Info

Publication number
MA51587B1
MA51587B1 MA51587A MA51587A MA51587B1 MA 51587 B1 MA51587 B1 MA 51587B1 MA 51587 A MA51587 A MA 51587A MA 51587 A MA51587 A MA 51587A MA 51587 B1 MA51587 B1 MA 51587B1
Authority
MA
Morocco
Prior art keywords
oligomer conjugates
muscular dystrophy
exon skipping
skipping oligomer
exon
Prior art date
Application number
MA51587A
Other languages
French (fr)
Other versions
MA51587A (en
Inventor
Gunnar J Hanson
Marco A Passini
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Priority claimed from PCT/US2017/066222 external-priority patent/WO2018118599A1/en
Publication of MA51587A publication Critical patent/MA51587A/en
Publication of MA51587B1 publication Critical patent/MA51587B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Des conjugués oligomère antisens capables de se lier à un site cible sélectionné du gène de la dystrophine humaine pour induire le saut de l'exon 51 sont décrites.Antisense oligomer conjugates capable of binding to a selected target site of the human dystrophin gene to induce skipping of exon 51 are described.

MA51587A 2016-12-19 2017-12-13 Exon skipping oligomer conjugates for muscular dystrophy MA51587B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662436182P 2016-12-19 2016-12-19
PCT/US2017/066222 WO2018118599A1 (en) 2016-12-19 2017-12-13 Exon skipping oligomer conjugates for muscular dystrophy

Publications (2)

Publication Number Publication Date
MA51587A MA51587A (en) 2019-10-23
MA51587B1 true MA51587B1 (en) 2022-09-30

Family

ID=65895706

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51587A MA51587B1 (en) 2016-12-19 2017-12-13 Exon skipping oligomer conjugates for muscular dystrophy

Country Status (2)

Country Link
AR (1) AR110389A1 (en)
MA (1) MA51587B1 (en)

Also Published As

Publication number Publication date
AR110389A1 (en) 2019-03-27
MA51587A (en) 2019-10-23

Similar Documents

Publication Publication Date Title
MA65895B1 (en) EXON SKIPPING-INDUCING OLIGOMERIC CONJUGATES FOR MUSCULAR DYSTROPHY
CY1125549T1 (en) EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
MA45618A (en) OLIGOMERIC EXON BREAKS FOR MUSCLE DYSTROPHY
EA201991450A1 (en) OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY
CY1121876T1 (en) EXON BYPASS COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DYSTROPHY
MY205772A (en) Exon skipping oligomer conjugates for muscular dystrophy
SA520420562B1 (en) Exon skipping oligomer conjugates for muscular dystrophy
IL268856A (en) Methods for the purification of messenger RNA
IL271389A (en) Non-viral DNA proceeds are intended
CY1123119T1 (en) ANTI-SENSE NUCLEIC ACID
EP3659050A4 (en) IMPROVEMENT OF MUSIC ALLOWING REPETITIVE MOVEMENT ACTIVITIES
EP3463290A4 (en) HIV-1 REACTION CONTROL BY GENETIC EDITION STRATEGY
EA201891317A2 (en) THERAPEUTIC TARGETS FOR CORRECTION OF HUMAN DISTROPHIN GENE BY EDITING GENES AND METHODS OF THEIR APPLICATION
WO2019241385A3 (en) Exon skipping oligomers for muscular dystropy
EP3347466A4 (en) DETERMINING THE NUMBER OF GENETIC COPIES USING SMASH NUCLEOTIDE HIGH SPEED MULTIPLEX SEQUENCING
EP3344650A4 (en) AAV-EPO FOR THE TREATMENT OF PETS
EP3673505A4 (en) INJECTION KIT FOR EPITAXIAL DEPOSIT PROCESSES
EP3367784A4 (en) ORGAN ENGINEERING HUMANIZED BY GENETIC COMPLETION
EA202191601A1 (en) OLIGOMER CONJUGATES FOR EXON SKIP IN MUSCULAR DYSTROPHY
MA51582B1 (en) Exon skipping oligomer conjugates for muscular dystrophy
MA51587B1 (en) Exon skipping oligomer conjugates for muscular dystrophy
MA47495A (en) ANTI-INFLAMMATORY COMPOSITIONS INCLUDING IRAQ AND JAK INHIBITORS
MA47015B1 (en) Exon skipping oligomer conjugates for muscular dystrophy
EP3363464A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER COMPRISING AN RNA OLIGONUCLEOTIDE
EP4219717A3 (en) Exon skipping oligomers for muscular dystrophy